Medicare AdvantagePrior AuthMedium impact
Yulithira (everolimus) (New)
Humana·Oncology, Internal Medicine·Medicare Advantage
We identified it
Jul 23, 2026
Summary
Humana has issued a new Prior Authorization policy for Yulithira (everolimus) affecting Medicare Advantage members. This is a 1-day-old policy requiring immediate review to determine coverage criteria, authorization requirements, and billing implications for this medication.
Action Required
Immediately: Billing and clinical teams must access the full policy document at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a584836 to extract specific coverage criteria, prior authorization requirements, and any associated HCPCS codes for Yulithira (everolimus). Update billing system to flag all Yulithira claims for Medicare Advantage members requiring prior authorization review before claim submission. Brief providers and pharmacy staff on new requirements. Note: Only summary information is currently available; detailed billing codes and effective dates cannot be confirmed without accessing the complete policy document.